Product image of Montelucaste Accord (Montelukast) supplied by GNH India

Montelucaste Accord

Active Ingredient:
Montelukast
Origin:
EU

Montelucaste Accord (Montelukast)

Montelukast, the active ingredient in Montelucaste Accord, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is employed to manage asthma, allergic rhinitis, and exercise‑induced bronchoconstriction in adults and children, and is indicated for long‑term control of these respiratory and allergic conditions.

GNH India supplies Montelucaste Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and consistent quality for global healthcare providers, and ensures compliance with international quality standards.

Manufacturer / TM Owner

Accord Healthcare S.L.U.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Montelukast acts on the leukotriene pathway to reduce airway inflammation and allergic responses.
  • Asthma (maintenance therapy): improves long‑term control of symptoms and reduces exacerbations.
  • Allergic rhinitis (seasonal or perennial): alleviates nasal congestion, sneezing and itching.
  • Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

How It Works

  • Montelukast selectively blocks the cysteinyl leukotriene receptor CysLT1 on airway smooth‑muscle cells, mast cells and eosinophils. By antagonizing this receptor, it prevents leukotrienes D4, E4 and related mediators from binding, thereby inhibiting bronchoconstriction, mucus secretion, vascular permeability and inflammatory cell recruitment that contribute to asthma and allergic rhinitis. The effect is dose‑dependent and contributes to improved pulmonary function over time.

Side Effects

Montelukast may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects

  • Headache: mild to moderate head pain.
  • Abdominal pain: discomfort or cramps in the stomach area.
  • Nausea: feeling of sickness or urge to vomit.
  • Upper respiratory infection: symptoms such as sore throat, runny nose or cough.
  • Diarrhea: loose stools.
  • Fatigue: feeling unusually tired.

Serious or Rare Side Effects

  • Allergic reactions: rash, itching, swelling, or anaphylaxis.
  • Neuropsychiatric events: agitation, depression, or suicidal thoughts.
  • Liver enzyme elevation: abnormal liver function test results.
  • Blood dyscrasias: rare cases of neutropenia or thrombocytopenia.

Precautions & Warnings

  • When prescribing Montelukast, clinicians should consider several precautionary measures to ensure safe use.
  • Assess asthma control: confirm that maintenance therapy is appropriate before initiating.
  • Monitor for neuropsychiatric symptoms: observe patients for mood changes or suicidal thoughts.
  • Use with caution in hepatic impairment: adjust therapy if liver disease is present.
  • Avoid in patients with known hypersensitivity to montelukast or excipients.
  • Pregnancy and lactation: evaluate risk‑benefit as safety data are limited.
  • Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture.

Avoid Interactions

Montelukast can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

  • Ritonavir: strong CYP3A4 inhibition may increase montelukast plasma levels, raising risk of adverse effects.
  • Phenobarbital: enzyme induction can lower montelukast concentrations, reducing therapeutic effect.

Moderate Interactions (Monitor Closely)

  • Fluconazole: moderate CYP3A4 inhibition may modestly increase exposure; monitor for side effects.
  • Carbamazepine: enzyme induction may decrease montelukast levels; consider dose adjustment.
  • Warfarin: occasional reports of altered INR; monitor coagulation parameters.

Frequently Asked Questions

Montelucaste Accord contains the active ingredient montelukast, which is prescribed to help control chronic asthma, relieve symptoms of seasonal or perennial allergic rhinitis, and prevent exercise‑induced bronchoconstriction. It is used as a maintenance therapy to reduce airway inflammation and improve breathing over time.

Montelukast works by selectively blocking the cysteinyl leukotriene receptor CysLT1 on cells in the respiratory tract. This inhibition prevents leukotrienes—potent inflammatory mediators—from binding, thereby reducing bronchoconstriction, mucus production, vascular leakage, and recruitment of inflammatory cells that contribute to asthma and allergic symptoms.

The appropriate dose of Montelucaste Accord is determined by a qualified prescriber based on the patient’s age, condition and clinical response. Dosing recommendations are provided in the prescribing information, and the healthcare professional will tailor the regimen to each individual’s needs.

Safety data for montelukast during pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss the risks and benefits with their healthcare provider.

To request Montelucaste Accord, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details and any required import documentation.

The primary alternative for asthma maintenance is inhaled corticosteroids, which act directly on airway inflammation. Montelukast, as a leukotriene receptor antagonist, offers an oral option that can be used alone or as add‑on therapy, especially when inhaled steroids are not tolerated or adherence to inhalers is challenging.

Montelucaste Accord should be stored at ambient temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and keep out of reach of children. No refrigeration is required for this oral dosage form.

Montelucaste Accord is taken orally, usually once daily in the evening. The tablet should be swallowed whole with a glass of water and not chewed, crushed or split unless specifically instructed by a healthcare professional.

Serious risks include neuropsychiatric events such as agitation, depression, anxiety, or suicidal thoughts, as well as severe allergic reactions like rash, swelling or anaphylaxis. Rarely, liver enzyme elevations or blood dyscrasias may occur. Patients should seek immediate medical attention if any of these symptoms develop.

Montelucaste Accord should be avoided in individuals with known hypersensitivity to montelukast or any of its excipients. It is also contraindicated in patients who have experienced severe allergic reactions to leukotriene‑modifying agents. Clinicians should assess each patient’s medical history before initiating therapy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Montelukast

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT